Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anthera aims to raise $47 million to advance varespladib in ACS

This article was originally published in Scrip

Executive Summary

Anthera Pharmaceuticals has priced a secondary public offering of 6.7 million shares of its common stock at $7.50 per share for proceeds of about $50 million. The company hopes to net $47 million from the offering (after expenses) – money that will help it move forward its lead compound, varespladib, which is in Phase III trials and targets an enzyme implicated in acute coronary syndrome.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts